The interrelationship between brown adipose tissue (BAT) and white adipose tissue (WAT) is emerging as an important factor in obesity, but the effect of impairing non-shivering thermogenesis in BAT on lipid storage in WAT remains unclear. To address this, we have characterized the metabolic phenotype of a mouse model for Costeff syndrome, in which a point mutation in the mitochondrial membrane protein Opa3 impairs mitochondrial activity. Opa3 L122P mice displayed an 80% reduction in insulin-like growth factor 1, postnatal growth retardation and hepatic steatosis. A 90% reduction in uncoupling protein 1 (UCP1) expression in interscapular BAT was accompanied by a marked reduction in surface body temperature, with a 2.5-fold elevation in interscapular BAT mass and lipid storage. The sequestration of circulating lipid into BAT resulted in profound reductions in epididymal and retroperitoneal WAT mass, without affecting subcutaneous WAT. The histological appearance and intense mitochondrial staining in intra-abdominal WAT suggest significant 'browning', but with UCP1 expression in WAT of Opa3 L122P mice only 62% of that in wild-type littermates, any precursor differentiation does not appear to result in thermogenically active beige adipocytes. Thus, we have identified Opa3 as a novel regulator of lipid metabolism, coupling lipid uptake with lipid processing in liver and with thermogenesis in BAT. These findings indicate that skeletal and metabolic impairment in Costeff syndrome may be more significant than previously thought and that uncoupling lipid uptake from lipid metabolism in BAT may represent a novel approach to controlling WAT mass in obesity.
INTRODUCTION
Mammals have two primary types of adipose tissue (AT), lipid-storing white fat (WAT) and lipid-burning brown fat (BAT). With the rising prevalence of obesity, attention has largely focused on the control of WAT mass, whereas BAT function was initially considered physiologically significant only in neonates and small rodents. However, the recent description of significant BAT deposits in adult humans (1, 2) , coupled with the discovery that the production of beige adipocytes (3) can be induced in intra-abdominal WAT (4 -6) by a 'browning' process, has excited interest in the potential of exploiting this mechanism to reduce lipid storage in WAT (7 -9) . This renewed study of BAT function has concentrated on the factors regulating the conversion of WAT to BAT (9-13), while little attention has been given to the consequences of manipulating the function of extant BAT.
The precise function of BAT in adult humans has yet to be fully elucidated, but it now appears that, as in neonates and small rodents, the mitochondria-rich brown adipocytes are the primary source of non-shivering thermogenesis (14) . In this process, b-adrenoceptor stimulation promotes the expression and activation of uncoupling protein 1 (UCP1) in the inner mitochondrial membrane, thereby increasing proton permeability and heat generation (15) . Since the energy substrates utilized in this process include the free fatty acids (FFAs), dysregulation of mitochondrial function in BAT has wider metabolic repercussions. For example, ablation of UCP1 not only abolishes diet-induced thermogenesis, but also elevates WAT mass (16) . However, given that BAT has recently been shown to be an important determinant of triglyceride clearance (17) , we reasoned that uncoupling mitochondrial activity from lipid uptake in BAT should promote lipid sequestration, thereby depleting the lipid available for storage in WAT.
To test this hypothesis, we characterized the metabolic phenotype in mice bearing a missense mutation in Opa3, the B6; C3-Opa3 L122P (Opa3
L122P
) mouse (18) . The Optic atrophy 3 (OPA3) gene encodes two ubiquitously expressed transcripts, OPA3A and OPA3B (19) . Opa3A (subsequently called Opa3) is a 179-amino acid peptide containing an N-terminal mitochondrial targeting sequence (20, 21) , directing expression to either the inner (22) or outer (23) mitochondrial membrane. Although the function of this protein has yet to be fully elucidated, it is known to induce mitochondrial fragmentation (21) . Mutations in Opa3A lead to the development of the hereditary optic neuropathy known as type III methylglutaconic aciduria (3-MGA) or Costeff syndrome (MIM 258501) (20, 24) . The Opa3 L122P mouse was selected for this study because our initial characterization of this model for Costeff syndrome included some evidence of intra-abdominal leanness (18) , thereby providing preliminary support for our hypothesis.
We have now performed a rigorous analysis of the metabolic phenotype of this model, demonstrating that, in addition to the classical Costeff phenotype (17), Opa3 L122P mice also display the profound disturbance in lipid metabolism predicted above. Our findings have significant implications for the alleviation of obesity and for patients with Costeff syndrome.
RESULTS

The Opa3
L122P mouse model for Costeff syndrome
Despite their normal birth weight, homozygous Opa3 L122P mice showed a progressive failure to thrive ( Fig. 1A and B) , weighing significantly less from P5 (P , 0.05) and only 40% of that in WT littermates at P30 (Fig. 1B and Table 1 ; P , 0.001). As in our initial characterization of this model (18) , heterozygous littermates showed no obvious impairment in weight gain (Fig. 1B) . Therefore, the remainder of our study was focused upon the phenotypic analysis of the homozygous mutants. The reduction in body weight in homozygous Opa3 L122P mice was accompanied by a 22% reduction in body (Fig. 1C ) and tibial lengths ( Fig. 1D ; P , 0.001) and an 80% reduction in circulating insulin-like growth factor 1 (IGF-1; Fig. 1E ; P , 0.001). In P30 Opa3 L122P mice, tibial epiphyseal plate width (234 + 32 mm), a marker of the rate of growth, was 86% of that in WT littermates (272 + 8 mm), but this was not statistically significant (P ¼ 0.140) due to the larger variation in plate widths in Costeff syndrome mice. More detailed analysis of the individual growth plate zones revealed that while there was no significant change in germinal zone width (Fig. 1F) , the number of cells in this zone was increased by 28% ( Fig. 1G ; P , 0.01). In contrast, the width of the proliferative zone in Opa3 L122P mice was reduced by 19% ( Fig. 1F ; P , 0.05), but without any significant alteration in the number of cells in this part of the column (Fig. 1G ). In the hypertrophic zone, there was no change in either zone width or cell number, although the variation in zone width was more marked in Costeff syndrome mice. Despite normal plasma osmolality, Opa3 L122P mice showed a 16-fold elevation in circulating 3-methylglutaconic acid (Table 1 ; P , 0.01), the key diagnostic feature of Costeff syndrome.
Plasma and hepatic lipid profiles in Costeff syndrome mice
The diet-derived sterol esters in the circulation were not significantly affected in Opa3 L122P mice (Table 1) . Liver weight was halved in Opa3 L122P mice (P , 0.0001; data not shown), but when corrected for body weight, proportionate liver weight was increased by 30% ( Fig. 2B ; P , 0.05).
Opa3
L122P livers showed evidence of hepatic steatosis ( Fig. 2A) , with a 9-fold increase in Oil Red-O staining ( Fig. 2E ; P , 0.05), characterized by large lipid rafts ( Fig. 2C and D) , with a similar increase in hepatic triacylglycerol (TAG) content ( Fig. 2F ; P , 0.05). Although total hepatic membrane lipid levels were unchanged (data not shown), the content of the mitochondrial-specific lipid, cardiolipin, and its metabolic precursor, phosphatidylglycerol, was increased by 49 and 92%, respectively (Fig. 2G ). Despite this increase in hepatic lipid storage, circulating TAG was not significantly reduced (Table 1) .
Brown AT in Costeff syndrome mice
With this evidence of hepatic lipid entrapment, we characterized the function of other tissues with an important role in lipid metabolism. Proportionate interscapular BAT weight was elevated 2.5-fold ( Fig. 3A ; P , 0.01), with parallel increases in total lipid area ( Fig. 3B-D ; P , 0.01) and lipid droplet size ( Fig. 3F ; P , 0.05), indicating that lipid uptake in Costeff syndrome mice is unimpeded. In contrast, mutation of Opa3 clearly impaired the metabolic output from BAT, with surface body temperature of Opa3 L122P mice 58C lower than that in WT littermates (Fig. 3G ) and UCP1 mRNA expression, a marker of thermogenic activity in BAT mitochondria, reduced by 90% ( Fig. 3J ; P , 0.01). This mitochondrial impairment occurred without any observable reduction in mitochondrial fluorescence, which remained clustered around the enlarged lipid droplets ( Fig. 3H and I) . Thus, the impairment of mitochondrial function in Costeff syndrome mice has effectively uncoupled lipid storage from lipid utilization in BAT.
Adiposity profile in Costeff syndrome mice
In view of this enhanced lipid sequestration in BAT, we quantified a range of indices of WAT mass in Opa3 L122P mice. As predicted by our hypothesis and indicated by our previous MRI data (18), Opa3 L122P mice showed a marked reduction in proportionate intra-abdominal (epididymal and retroperitoneal) WAT weight ( Fig. 4A and E; P , 0.01), attributable to a 71% reduction in adipocyte size ( Fig. 4B-D ; P , 0.001). This did not appear to be due to elevated lipolysis, as circulating FFAs were not significantly increased (Table 1) , but is consistent with reduced lipid uptake. Similarly, although intra-abdominal WAT from Opa3 L122P mice showed clear areas of 'browning', with a shift from large unilocular to small multilocular lipid droplets (arrowheads in Fig. 4C ) and areas of more intense mitochondrial staining ( Fig. 4G and H), UCP1 mRNA expression was not increased ( Fig. 4I ; Opa3 mutant 62% of WT; P ¼ 0.054). Thus, the 'browning' of WAT in the Opa3 L122P model for Costeff syndrome did not result in functional, thermogenically active beige adipocytes. In contrast, proportionate inguinal WAT mass, a deep subcutaneous depot, was not significantly affected ( Fig. 4F ).
DISCUSSION
Costeff syndrome is one of four types of 3-MGA and is characterized by early-onset bilateral optic atrophy and reduced visual acuity, with late-onset spasticity, extrapyramidal dysfunction and cognitive impairment. We have recently generated a mouse model for this condition, in which a missense mutation of the mitochondrial membrane protein, Opa3, results in visual impairment with cell loss in the retinal ganglion and atrophy of the optic nerve (18) . Although the L122P mutation does not disrupt the subcellular localization of Opa3 or the degree of mitochondrial fragmentation, retinal mitochondria display slight alterations of cristae morphology (25) and elevated opacity (18) . In the current study, we demonstrate that these mice not only show a dramatic increase in circulating 3-methylyglutaconic acid, diagnostic for Costeff syndrome, but display a more widespread mitochondrial impairment leading to profound lipodystrophy. Indeed, our findings are not only significant for patients with Costeff syndrome, but have wider implications for the functional relationship between BAT and WAT in the regulation of fat mass. In BAT, the mitochondria-rich adipocytes utilize carbohydrates and FFAs to generate heat. The BAT-specific protein, UCP1 dissipates the electrochemical proton gradient across the inner mitochondrial membrane to mediate adaptive thermogenesis, thereby also regulating triglyceride clearance and the lipid available for storage in WAT (17) . We reasoned that uncoupling lipid uptake from lipid utilization in BAT should transform BAT into a lipid storage depot, thereby depleting lipid supply to WAT. Our characterization of lipid homeostasis in the Opa3 L122P model for Costeff syndrome supports this hypothesis.
In Costeff syndrome mice, mutation of mitochondrial Opa3 clearly impairs non-shivering thermogenesis, as indicated by the dramatic decrease in surface body temperature and the virtual abolition of UCP1 expression in interscapular BAT. This evidence of mitochondrial impairment occurred without any observable reduction in mitochondrial fluorescence, which remained clustered around the unstained lipid droplets. However, this reduction in lipid utilization did not appear to inhibit lipid uptake, with droplet size and BAT weight increasing in parallel. Thus, impairing mitochondrial function in BAT of Opa3 L122P mice has effectively dissociated lipid storage from lipid utilization.
The presence of lipid-engorged BAT was accompanied by a dramatic reduction in intra-abdominal WAT mass, the smaller adipocyte size being consistent with reduced substrate supply. This does not appear to be due to impaired absorption of the diet-derived lipids in the gastrointestinal tract, as the circulating sterol esters remain within the physiological range. Similarly, although the severe hepatic steatosis indicates lipid entrapment in the liver, the absence of a significant decline in circulating TAG suggests that the diet-derived lipids continue to be processed and released, albeit at a lower rate than the combined rates of uptake and synthesis. However, the net result of the Opa3 L122P mutation in Costeff syndrome mice is the sequestration of circulating lipoprotein by BAT (17), the remaining circulating substrate being insufficient to maintain WAT mass.
This combination of elevated BAT mass and profound intra-abdominal leanness is unusual. In UCP1-null mice, increased reliance on shivering thermogenesis (26) and elevated lipid accumulation in BAT (27, 28) are accompanied by normal WAT mass under the housing temperatures used in the current study (27) . Indeed, under thermoneutral conditions, UCP1-null mice develop obesity (16) , the inhibition of BAT activity increasing the availability of surplus circulating lipid for uptake into WAT. While it remains possible that susceptibility to obesity may be similarly enhanced in Opa3 L122P mice, the profound leanness in these animals suggests that a dramatic increase in ambient temperature may be required to suppress lipid uptake in BAT sufficiently to induce an observable elevation in WAT mass.
The appearance and site-specific nature of the altered WAT phenotype in Opa3 L122P mice also deserve comment. Histological examination revealed a shift from large unilocular to small multilocular lipid droplets in intra-abdominal WAT, accompanied by areas of intense mitochondrial staining. Although our fluorescent visualization of mitochondria did not permit discrimination between increased mitochondrial number and size, our data suggest significant 'browning' of intra-abdominal WAT, possibly as a homeostatic response to hypothermia. However, the lack of an increase in UCP1 expression indicates that differentiation of myf-5-independent precursors (3) in WAT does not result in functional, thermogenically active beige adipocytes.
Interestingly, the profound reduction in WAT mass in intra-abdominal depots was not seen in subcutaneous WAT, adding weight to our argument that the hypothermia we observed in Opa3 L122P mice is more likely to result from reduced thermogenesis than increased heat loss. This WAT distribution may also have further physiological repercussions. For example, expansion of intra-abdominal WAT is the primary determinant of developing the metabolic syndrome (29) , whereas a specific reduction in epididymal WAT results in suppression of spermatogenesis (30) . In addition, given the reciprocal relationship between marrow adiposity and both bone formation (31) and haematopoiesis (32), the 10-fold elevation in marrow adiposity also observed in Opa3 L122P mice (data not shown) suggests that bone structure and strength as well as red cell formation may also be significantly compromised in this model.
In this context, it is evident that the growth of the skeleton in Opa3 L122P mice is significantly impaired, tibial length being markedly reduced in line with the profound reduction in circulating IGF-1. Although, total epiphyseal plate width, an index of the rate of skeletal growth, was not significantly reduced at termination, the increased number of cells in the germinal zone suggests that growth hormone (GH) secretion may be elevated in line with reduced IGF-1 feedback (33). This is, however, difficult to substantiate in mice, as quantification of the spontaneous episodes of GH secretion has proved to be technically demanding, particularly in dwarf strains. In contrast, the number of chondrocytes within the proliferative zone, which undergo clonal expansion in response to IGF-1, appears to be normal. This suggests either that IGF-binding protein production is modified to maintain adequate levels of free circulating IGF-1, or that there is sufficient local IGF-1 production to support chondrocyte proliferation. While it is possible that impairment of mitochondrial function may contribute directly to the observed growth phenotype, loss of mitochondrial activity in the growth plate is usually associated with chondrocyte apoptosis, particularly in the hypertophic zone (34) (35) (36) . Since this band of the plate appears relatively normal in this model, we consider that the growth phenotype is most likely to result from the profound reduction in circulating IGF-1. Despite this evidence for growth retardation in Costeff syndrome mice, there are no extant reports of a skeletal phenotype in patients with this condition, although growth retardation is part of the spectrum of symptoms of both Type II [Barth syndrome (37) ] and Type V [dilated cardiomyopathy ataxia syndrome (38)] 3-MGA. This interplay between GH and IGF-1 may also contribute to the observed hepatic phenotype. The severity of the hepatic steatosis in Costeff syndrome mice is remarkable, particularly in the context of the relatively normal levels of circulating diet-derived lipids and TAG. Although a similar hepatic phenotype occurs in mice with hepatocyte-specific ablation of the GH receptor (39), the magnitude of the reduction in IGF-1 observed here would normally be expected to result in elevated GH secretion (33) . There is also compelling evidence that low circulating IGF-1 is itself associated with nonalcoholic fatty liver disease (40, 41) . However the lack of hepatic steatosis in mice with hepatocyte-specific deletion of IGF-1 (42) suggests that, while the hepatic phenotype in Costeff syndrome mice may accompany low circulating IGF-1, it is most likely to result from impaired mitochondriadependent processing of dietary lipids.
This study raises the question of the functional relationship between Opa3 and lipid metabolism. A recent preliminary report indicated that Opa3 binds to prohibitin (43) , a molecular chaperone with additional roles in insulin/IGF-1 signalling (44) and maintaining the integrity of the inner mitochondrial membrane (45) . As a chaperone, prohibitin shuttles cardiolipin between the mitochondria and the nucleus (46); a form of inter-organelle communication that appears most important in tissues with high oxygen demands (e.g. the retinal pigment cells (47) and thermogenically stressed brown adipocytes). Thus, failure of Opa3 to anchor prohibitin to the inner mitochondrial membrane in Costeff syndrome mice would render such tissues susceptible to hypoxia and oxidative stress. This would not only account for the retinal cell loss previously described in this model (18) , but would also lead to the dissociation of lipid uptake and utilization in BAT and the compensatory elevation in cardiolipin and its precursor, phosphatidylglycerol described in this study.
Our findings have significant metabolic implications for individuals with Costeff syndrome. Our data suggest that the WAT phenotype of mice with impaired mitochondrial function, such as the Opa3 L122P -mutant, may be dependent upon the thermogenic load placed upon the BAT. Thus, the absence of any reports of metabolic disturbance in individuals with Costeff syndrome may arise from the fact that the majority of the identified kindreds (20, 24) reside in regions near the upper critical air temperature (48) , where the thermogenic load is low. Therefore, in the context of a minimal requirement for mitochondrial thermogenesis in BAT, lipid storage in WAT may appear normal in these individuals. Although our study indicates that examination of BAT function in these patients may now be timely, the role of ambient temperature and BAT function in the development of obesity in cooler climates may be more pressing.
In summary, the uncoupling of thermogenic activity from lipid uptake in the Opa3 L122P mouse model for Costeff syndrome switches the function of BAT from energy utilization to energy storage. The consequent entrapment of lipid in BAT is accompanied by a profound reduction in intra-abdominal WAT mass. Thus, we have identified the mitochondrial membrane protein Opa3 as a novel regulator of lipid metabolism and homeostasis. When combined with recent reports that OPA1 acts as an A-kinase anchoring protein to trigger lipolysis (49) and regulate fat mass and thermogenesis (50), it is becoming clear that the optic atrophy proteins have a wider metabolic significance than their name suggests. Indeed, BAT-specific inhibition of Opa3 function to enhance lipid storage or lipid utilization in BAT may represent a novel approach to reducing intra-abdominal fat mass, to curtail the current epidemic in obesity.
MATERIALS AND METHODS
Animals
The procedures described conformed to the institutional and national guidelines for animal experimentation and were specifically approved by local ethical review. One cohort of homozygous Opa3 L122P mice, together with their heterozygous and WT littermates, were weighed daily from birth until 50 days of age. In all subsequent analyses, data were obtained from 30-day-old homozygous male Opa3 L122P mice and WT littermates killed by decapitation after isofluorane anaesthesia.
Growth
Tibiae were dissected and the length determined with a handheld micrometer. The rate of skeletal growth at termination was assessed by quantification of tibial epiphyseal plate widths as previously described (51) . In brief, tibiae were fixed in 10% buffered formal saline, decalcified in 10% EDTA and embedded in paraffin wax prior to the collection of 7 mm longitudinal/anterior-posterior sections (3 per bone). Epiphyseal plate widths, individual zone widths and the number of cells across each zone were quantified in Masson's trichrome-stained sections using a Leica DM-LB microscope with Leica Q-Win software. Total plasma IGF-1 and osmolality were determined in terminal samples by ELISA (IDS Ltd, Tyne and Wear, UK) and vapour pressure osmometry (Wescor Inc., Logan, UT, USA).
Quantification of 3-methylglutaconic acid
Given the difficulty in obtaining urine from Opa3 L122P mice, we quantified 3-methylglutaconic acid in terminal plasma samples by gas chromatography and mass spectrometry (GC -MS). 3-Methylglutaconic acid was extracted with ethyl acetate (3 × 3 ml) and diethyl ether (3 × 3 ml) and derivatized with N,O-bis(trimethylsilyl)trifluoroacetamide and pyridine (1:1, v/v) at 708C for 30 min, with pentadecanoic acid (C15:0) added as an internal standard. Trimethylsilyl (TMS) derivatives of 3-methylglutaconic acid were analysed by GC -MS using an Agilent 6890N GC with 5973N MS and a 7683 autosampler fitted with 30 m × 0.25 mm i.d. column (Agilent HP-5MS, phase thickness 0.25 mm). Two-microlitre samples were injected at 2308C using a 50:1 split ratio. The column was temperature programmed from 80 to 2708C at 108C/min, then held at 2708C for 20 min using helium as a carrier gas at a constant pressure of 13.43 psi. Characteristic ion for di-TMS of 3-methylglutaconic acid at m/z 288 was used to monitor the separation of 3-methylglutaconic acid. Quantification was made by reference to the C15:0 internal standard.
Hepatic lipid profile in Costeff syndrome mice
Livers were dissected whole and weighed. Stored lipid was visualized in cryostat sections with Oil Red-O, counterstained with Meyer's haematoxylin, hepatic lipid droplets being quantified as previously described (52) . Plasma and hepatic lipid profiles (TAG, total and individual phospholipids) were separated by TLC and quantified by their fatty acids using GC.
Brown AT in Costeff syndrome mice
Interscapular BAT was dissected, freed of surrounding WAT and weighed. One lobe was fixed in buffered formal saline and lipid droplets quantified on digital images of Masson's trichrome-stained sections as previously described for WAT (53) . Thermal images of live female WT and Opa3 L122P mice were obtained using an FLIR A40 camera (FLIR Systems, Boston MA, USA). Mitochondria were visualized on 7 mm paraffin-embedded sections of interscapular BAT using the Mito-ID TM Red Detection Kit (Enzo Life Sciences, Exeter, UK), with nuclei visualized by mounting in Vecatshield with DAPI (Vector Laboratories, Burlingame, CA, USA). UCP1 mRNA expression was quantified in intrascapular BAT by quantitative real-time PCR (qPCR) in compliance with the published MIQE guidelines (53) . Oligonucleotide primers for mouse UCP-1 were purchased from Primer Design (Southampton, UK: UCP-1 sense primer, GGTAAAAACAAGATTCATCAACTCTC: UCP-1 antisense primer, TCGCAGAAAAGAAGCCACAA), with individual samples normalized to the expression of b-actin [ACTB Primer mix (Primer Design, Catalogue # ge-SY-6; Batch # 12474)], which demonstrated invariant expression between samples. The quantity of cDNA in each reaction calculated by reference to a standard curve constructed from serial dilutions of pooled cDNA from WT BAT, the highest standard being assigned an arbitrary value of 1 (54) .
Adiposity profile in Costeff syndrome mice
Epididymal, retroperitoneal and inguinal WAT were dissected and weighed. Adipocyte size was quantified on Masson's trichrome-stained sections of epididymal WAT as previously described (52) . Visualization of mitochondria and quantification of UCP1 mRNA expression was performed on epididymal and retroperitoneal WAT, respectively, as described for BAT above.
Statistics
All results are expressed as mean + SEM, and differences between groups were compared by unpaired Student's t-test using GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA), with P , 0.05 considered significantly different.
